340 related articles for article (PubMed ID: 33705876)
21. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery.
Hoe S; Ivey JW; Boraey MA; Shamsaddini-Shahrbabak A; Javaheri E; Matinkhoo S; Finlay WH; Vehring R
Pharm Res; 2014 Feb; 31(2):449-65. PubMed ID: 23974958
[TBL] [Abstract][Full Text] [Related]
22. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
[TBL] [Abstract][Full Text] [Related]
23. Engineering the right formulation for enhanced drug delivery.
Ke WR; Chang RYK; Chan HK
Adv Drug Deliv Rev; 2022 Dec; 191():114561. PubMed ID: 36191861
[TBL] [Abstract][Full Text] [Related]
24. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
25. A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide.
Glieca S; Cavazzini D; Levati E; Garrapa V; Bolchi A; Franceschi V; Odau S; Ottonello S; Donofrio G; Füner J; Sonvico F; Bettini R; Montanini B; Buttini F
Eur J Pharm Sci; 2023 Dec; 191():106609. PubMed ID: 37838239
[TBL] [Abstract][Full Text] [Related]
26. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
27. Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.
Chang RYK; Chan HK
Pharm Res; 2022 Dec; 39(12):3047-3061. PubMed ID: 36071354
[TBL] [Abstract][Full Text] [Related]
28. Formulation Design of Dry Powders for Inhalation.
Weers JG; Miller DP
J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
30. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
31. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
32. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
33. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
34. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
35. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
[TBL] [Abstract][Full Text] [Related]
36. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
37. Formulation of spray dried enzymes for dry powder inhalers: An integrated methodology.
Fernandes DA; Costa E; Leandro P; Corvo ML
Int J Pharm; 2022 Mar; 615():121492. PubMed ID: 35063592
[TBL] [Abstract][Full Text] [Related]
38. Dry-powder formulations of non-covalent protein complexes with linear or miktoarm copolymers for pulmonary delivery.
Nieto-Orellana A; Coghlan D; Rothery M; Falcone FH; Bosquillon C; Childerhouse N; Mantovani G; Stolnik S
Int J Pharm; 2018 Apr; 540(1-2):78-88. PubMed ID: 29425761
[TBL] [Abstract][Full Text] [Related]
39. Physical stability of dry powder inhaler formulations.
Shetty N; Cipolla D; Park H; Zhou QT
Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
[No Abstract] [Full Text] [Related]
40. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
